Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?

被引：4
|
作者：
Duerr, Donat [1 ]
Siciliano, Raffaele Daniele [1 ]
Hummel, Yvonne [1 ]
O'Meara, Alix [1 ]
Hirschi, Anita [1 ]
Burkhard, Roger [1 ]
Honegger, Hanspeter [1 ]
机构：
[1] Stadtspital Triemli, CH-8063 Zurich, Switzerland
来源：
ANNALS OF HEMATOLOGY | 2010年 / 89卷 / 01期
关键词：
DELETION; MANAGEMENT; DEL(5Q);
D O I：
10.1007/s00277-009-0775-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [31] Familial occurrence of myelodysplastic syndrome with del(5q)
    Volpicelli, Paola
    Latagliata, Roberto
    Carmosino, Ida
    Breccia, Massimo
    Vozella, Federico
    Mancini, Marco
    Cannella, Laura
    Alimena, Giuliana
    LEUKEMIA & LYMPHOMA, 2011, 52 (06) : 1143 - 1145
  • [32] Molecular Dissection of the 5q Deletion in Myelodysplastic Syndrome
    Ebert, Benjamin L.
    SEMINARS IN ONCOLOGY, 2011, 38 (05) : 621 - 626
  • [33] A NEW CRITICAL DELETION OF 5Q IN MYELODYSPLASTIC SYNDROME
    PHILLIPS, CN
    PRIEST, JH
    VOGLER, WR
    CLINICAL RESEARCH, 1984, 32 (05): : A885 - A885
  • [34] Cryptic 5q deletion in a patient with myelodysplastic syndrome
    Medlock, Ruth
    Barrans, Sharon
    Cargo, Catherine
    Kelly, Richard
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (03) : 347 - 347
  • [35] Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes
    Heise, Carla
    Carter, Troy
    Schafer, Peter
    Chopra, Rajesh
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) : 1663 - 1672
  • [36] Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide
    Gerds, Aaron T.
    List, Alan F.
    Giagounidis, Aristoteles
    Hellstrom-Lindberg, Eva
    Li, Jack Shiansong
    Swern, Arlene S.
    Sugrue, Mary M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [37] Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations
    Mallo, Mar
    del Rey, Monica
    Ibanez, Mariam
    Jose Calasanz, Ma
    Arenillas, Leonor
    Jose Larrayoz, Ma
    Pedro, Carmen
    Jerez, Andres
    Maciejewski, Jaroslaw
    Costa, Dolors
    Nomdedeu, Meritxell
    Diez-Campelo, Maria
    Lumbreras, Eva
    Gonzalez-Martinez, Teresa
    Marugan, Isabel
    Such, Esperanza
    Cervera, Jose
    Cigudosa, Juan C.
    Alvarez, Sara
    Florensa, Lourdes
    Hernandez, Jesus Ma
    Sole, Francesc
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (01) : 74 - 86
  • [38] Long term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome without del 5q cytogenetic abnormalities.
    Raza, Azra
    Reeves, James E.
    Feldman, Eric J.
    Deeg, H. Joachim
    Dreisbach, Luke
    Schiffer, Charles A.
    Shammo, Jamile M.
    Klimek, Virginia M.
    Greenberg, Peter L.
    Bennett, John M.
    DeWald, Gordon W.
    Zeldis, Jerome B.
    Wride, Kenton
    Schmidt, Michele
    Knight, Robert D.
    List, Alan F.
    BLOOD, 2006, 108 (11) : 78A - 78A
  • [39] Survival of Patients with Del(5q) Syndrome in the Lenalidomide Era
    Reagan, John L.
    Ollila, Thomas
    Dubielecka, Patrycja M.
    Olszewski, Adam J.
    BLOOD, 2016, 128 (22)
  • [40] LENALIDOMIDE TREATMENT IN 5Q(-) SYNDROME: A SINGLE CENTER EXPERIENCE
    Uskudar, H. Teke
    Andic, N.
    Gunduz, E.
    Ozpolat, S.
    Aras, B. Durak
    Akay, O.
    LEUKEMIA RESEARCH, 2015, 39 : S98 - S99
12345